Skip to content
OpenCapital
Get started

Gyre Therapeutics, Inc. GYRE Fair Value Adjustment of Warrants

Segments

By segment

See full
Gyre-$89K+96.1%
All Other Segments$0—
Gyre Pharmaceuticals$0—

Other financials

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10—

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation

See full
Market cap$694.58M-4.7%
Enterprise value$657.9M-8.0%
P/S5.9×-1.3×

Profitability

See full
Gross margin95.1%-1.1pp
Operating margin-0.1%-10.4pp
Net margin6.3%+3.3pp
FCF margin2.6%—

Returns & leverage

See full
Return on equity8.2%+4.2pp
Debt / equity0×0.0×
Current ratio4.6×+1.0×